Rallybio Corporation (RLYB), a clinical-stage biotechnology company focused on developing therapies for severe and rare diseases, demonstrates a permissible core business model under Shariah principles. However, its financial metrics, particularly the high liquidity ratio (212.44%) and interest income ratio (427.83%), result in non-compliance across major screening standards due to excessive exposure to riba (interest). The company maintains low debt levels (0.45%), which is compliant, and no non-permissible business activities. Despite strong ESG alignment with low risk in environmental, social, and governance factors, the overall compliance status is determined by index exclusion. Investors may consider monitoring for potential financial restructuring to achieve compliance, with purification required for any impure income.